Telephone: 608-265-2543; Fax: 608-890-3479
Embryonic Stem Cells/Induced Pluripotent Stem Cells
Version of Record online: 16 NOV 2011
Copyright © 2011 AlphaMed Press
Volume 29, Issue 12, pages 1975–1982, December 2011
How to Cite
Yoo, Y. D., Huang, C. T., Zhang, X., Lavaute, T. M. and Zhang, S.-C. (2011), Fibroblast Growth Factor Regulates Human Neuroectoderm Specification Through ERK1/2-PARP-1 Pathway. STEM CELLS, 29: 1975–1982. doi: 10.1002/stem.758
Author Contribution: Y.Y.: conception and design, collection and/or assembly of data, data analysis and interpretation, and manuscript writing; C.H. and T.M.L.V.: collection and/or assembly of data and data analysis and interpretation; X.Z.: data analysis and interpretation; and S.-C.Z.: conception and design, financial support, collection and/or assembly of data, data analysis and interpretation, manuscript writing, and final approval of manuscript.
Disclosure of potential conflicts of interest is found at the end of this article.
First published online in STEM CELLSEXPRESS October 13, 2011.
- Issue online: 16 NOV 2011
- Version of Record online: 16 NOV 2011
- Accepted manuscript online: 13 OCT 2011 09:39AM EST
- Manuscript Accepted: 20 SEP 2011
- Manuscript Received: 25 MAY 2011
- National Institute of Neurological Disorders and Stroke. Grant Number: R01 NS045926
- Waisman Center
- National Institute of Child Health and Human Development. Grant Number: P30 HD03352
Additional Supporting Information may be found in the online version of this article.
|STEM_758_sm_supplFigure1.pdf||115K||Supplemental Figure 1. Summary of gene expression changes in the FGF signaling pathway during hESC neural differentiation. Reported changes are ratios of expression values of samples from day 6 or day 10 compared to day 0 (ESC stage). Yellow boxes indicate no change in expression from ESC stage to day 6 or day 10. Red boxes indicate an increase in expression level and green boxes indicate downregulation.|
|STEM_758_sm_supplFigure2.tif||1851K||Supplemental Figure 2. hESCs (d0) and differentiating cells at day 2 (d2), d4 , d6, d8, and d10 were subjected to immunoblotting assay with Ab-PAR, -PARP-1, -ERK, -p-ERK as indicated.|
|STEM_758_sm_supplFigure3.pdf||302K||Supplemental Figure 3. hESC lines expressing PARP-1-shRNA and control shRNA. GFP was used as a viral marker.|
|STEM_758_sm_supplFigure4.pdf||79K||Supplemental Figure 4. PARP-1 knockdown inhibits neural differentiation of hESCs. The expression of PAX6 and SOX2 in PARP-1-knockdown cell lines at day10 of differentiation was assessed by flowcytometry. The value of each cell line was normalized to its own IgG control. The mean ± S.E. of relative value of PAX6 or SOX2 expressing cells from three independent experiments are shown after normalization to that of control RNAi. *, P<0.05, **, P>0.05 in comparison with the value from control cell line.|
|STEM_758_sm_supplFigure5.pdf||120K||Supplemental Figure 5. Neural differentiating PARP-1 knockdown (#3) or control cells at day10 were fixed and subjected to immunostaining with Ab- PARP-1, PAX6 or SOX2 as indicated. All cells express GFP, a viral marker.|
|STEM_758_sm_supplFigure6.pdf||74K||Supplemental Figure 6. Lysates from cell lines expressing PARP-1-shRNA and control shRNA at differentiating day 10 (d10) were subjected to immunoblotting with Abs against other lineage markers, Cytokeratin (epidermal), Brachiury (early mesodermal) and SOX17 (endodermal) as indicated.|
|STEM_758_sm_supplTable1.pdf||230K||Supplementary Table 1. Primer list|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.